Morgan Stanley Maintains Equal-Weight on Summit Materials, Lowers Price Target to $37

Morgan Stanley analyst Courtney Yakavonis maintains Summit Materials (NYSE:SUM) with a Equal-Weight and lowers the price target from $41 to $37.

byBenzinga Newsdesk

May 6, 2022

1 minute read

Morgan Stanley analyst Courtney Yakavonis maintains Summit Materials (NYSE:SUM) with a Equal-Weight and lowers the price target from $41 to $37.

Goldman Sachs Maintains Neutral on Equity Residential, Lowers Price Target to $74

By Benzinga Newsdesk

October 18, 9:20 AM

Goldman Sachs analyst Chandni Luthra maintains Equity Residential (NYSE:EQR) with a Neutral and lowers the price target from $86 to $74.

EQR

Mirion Technologies To Divest Biodex Physical Medicine For $5M In Cash, Up To Additional $3M In Deferred Cash Payments

By Michael Horton

November 29, 5:16 PM

Mirion Technologies, Inc. (NYSE:MIR) announced today that it has entered into a definitive agreement to sell the physical medicine assets of Biodex Medical Systems, Inc. ("Biodex") to Salona Global Medical

MIR

Analyst Ratings

Morgan Stanley Maintains Overweight Rating for Inari Medical: Here’s What You Need To Know

By Benzinga Insights

July 15, 12:08 PM

Morgan Stanley has decided to maintain its Overweight rating of Inari Medical (NASDAQ:NARI) and lower its price target from $108.00 to $93.00. Shares of Inari Medical are trading up 0.74% over the last 24 hours, at $73.70 per share.

NARI

JP Morgan Maintains Overweight on GXO Logistics, Lowers Price Target to $86

By Benzinga Newsdesk

April 8, 8:07 AM

JP Morgan analyst Brian Ossenbeck maintains GXO Logistics (NYSE:GXO) with a Overweight and lowers the price target from $100 to $86.

GXO

Morgan Stanley Maintains Equal-Weight on Summit Materials, Lowers Price Target to $37

Related Posts

Goldman Sachs Maintains Neutral on Equity Residential, Lowers Price Target to $74

Mirion Technologies To Divest Biodex Physical Medicine For $5M In Cash, Up To Additional $3M In Deferred Cash Payments

Morgan Stanley Maintains Overweight Rating for Inari Medical: Here’s What You Need To Know

JP Morgan Maintains Overweight on GXO Logistics, Lowers Price Target to $86